用于心力衰竭的一类新型治疗药物,高效和选择性的GRK2抑制剂,在体外研究中表现出增强的β-肾上腺素信号传导能力。HTS将衍生物5和1,2,4-三唑衍生物24a鉴定为命中化合物。新一代的脚手架和所有部分的SAR研究都产生了带有N-苄基羧酰胺部分的4-甲基-1,2,4-三唑衍生物,对GRK2的活性很高,对其他激酶的选择性更高。在亚型选择性方面,这些化合物对GRK1、5、6和7表现出足够的选择性,并且对GRK3具有几乎相同的抑制作用。我们的药物化学努力导致发现了115h(GRK2 IC 50= 18 nM),获得了与人GRK2和GRK2抑制剂的共晶体结构,该抑制剂增强了β-肾上腺素能受体(βAR)介导的cAMP积累,并防止了用异丙肾上腺素处理过的表达β2AR的HEK293细胞中βAR的内在化。因此,115h似乎是心力衰竭治疗的一种新型疗法。
Synthesis, molecular structure and multiple biological activities of N-(3-methoxyphenyl)-3-(pyridin-4-yl)-1H-pyrazole-5-carboxamide
摘要:
A new molecule of pyridylpyrazole amide (PPA) was successfully synthesized and systematically characterized by using NMR, ESI-MS and absorption (FT-IR and UV-Vis) spectroscopic techniques. The UV-Vis spectral absorption and infrared frequencies were theoretically calculated and compared with observed results. The in vitro biological applications like anti-inflammatory, antioxidant and antidiabetic activities were performed. It exhibited admirable anti-inflammatory activity and antidiabetic, worthy antioxidant activities than standards. The interactions between enzyme-ligand were identified with alpha-amylase (1HNY.pdb) using the autodock tool. Further Potential energy scan, fukui function and molecular electrostatic potential (MEP) were performed using DFT methods. Finally, In silico pharmacological studies like ADME were implemented for PPA. (C) 2019 Elsevier B.V. All rights reserved.
ide chalcones (6a–o), were synthesized as new hybrids with enriched biologicalactivities compared to their parent molecules. The compounds were characterized by 1H NMR, 13C NMR, Mass and IR spectral studies. Their antibacterial, anti-inflammatory and antioxidant activities have been evaluated. These compounds showed moderate to good antibacterial, anti-inflammatory and antioxidant activities. The
合成了十五个新的化学实体,即3-(吡啶-4-基)-1H-吡唑-5-羧酰胺查耳酮(6a – o),作为新的杂种,与它们的母体分子相比具有丰富的生物活性。化合物通过1 H NMR,13 C NMR,质谱和IR光谱进行表征。已经评估了它们的抗菌,消炎和抗氧化活性。这些化合物显示出中等至良好的抗菌,消炎和抗氧化活性。用环氧合酶进行分子对接分析,以确定可能的结合模型。